Improvement of in Vitro Fertilization Implantation by Soluble CD146 Dose in Embryonic Culture Environment

NCT ID: NCT03785119

Last Updated: 2018-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

318 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-31

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study of implantation potential of the embryo stay a priority in In Vitro Fertilization (IVF). Indeed, the selection of embryos to transfer is actually based in routine check on morphologic criteria, approved by literature but not perfect. Implantation's markers identification, allowing to choose the embryo(s) to transfer and then decrease pregnancy failure, represent a major issue in IVF, not any biomarker being approved yet.

Among factors regulating embryonic implantation, investigators have recently proposed soluble CD146, coming from proteolytic cleavage of the CD146 membrane, angiogenic bond molecule.

In a monocentric study about 222 transferred embryos at the end of IVF try, investigators showed that the sCD146 dose in the embryonic culture environment reflected the implantation ability of embryo, a high rate showing a low implantation potential and this independently of the embryonic quality. A multicentric prospective study is now required to confirm the utility of this dosage in clinical practice.

Primary objective : Compared 2 frozen embryo transfer (FET) strategies in terms of implantation efficiency, according to choice method of embryo to be transferred :

* Group A : Standard strategy : Depending on embryonic quality according to criteria currently selected.
* Group B : Experimental strategy : Association of embryonic quality according to criteria currently selected and of sCD146 rate.

Expected Results :

* Demonstrate a beginning pregnancy test significantly superior in Group B compared to Group A.
* Confirmed that sCD146 is an independent biomarker of morphologic embryonic quality (actual selection criteria) and represent a complementary criteria to choose embryos to transfer.

Methodology :

\- Multicentric prospective study with 2 groups of Frozen Embryo Transfer (FET); The calculation of the number of staff required includes 151 couples per group.

For this will be include for 24 months, couples benefiting of freezing at least one of the two embryos and transfer of only one FET.

* Test the same day of environment freezing where frozen embryos were cultivated. sCD146 dosage by ELISA technic (Enzyme Linked ImmunoSorbent Assay) in thus culture environment before FET.
* Implantation potential analyze of each transfer embryo (FET) according to sCD146 rate.
* Following of the FET future(pregnancy, childbirth) : maximum 9 months after attempt to each included couple.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

in Vitro Fertilization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard strategy

According to embryo quality (morphologic criteria)

No interventions assigned to this group

Experimental strategy

Association of embryo quality and sCD146 rate

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged \[18;42\] years
* Men aged \> 18 years
* Trying an IVF with :
* Frozen supernumerary embryo after fresh embryo transfer realised at the end of the try or frozen embryo (frozen all), without immediately transfer possibility (ovulation hyperstimulation context/ hyperprogesteronemia for example)
* Freezing at least 2 embryos frozen separately (1/vial)
* Whatever attempt rank
* Whatever MAP (Medically Assisted Procreation) technics (IVF/ICSI)
* Potential transfer of one frozen embryo
* Volunteer couples to participate at the study, received informations about this protocol and giving both their non opposition


\- FET realization in the selected population

Exclusion Criteria

* Refusal to participate at the study of at least one member of the couple
* Inclusion realized for a previous attempt
* IVF try with a third-party
* IVF try without embryo freezing
* Freezing only one embryo
* Non separately freezing of embryos (2/vial)
* Female patients \<18 years and \>42 years
* Male patients \<18 years
Minimum Eligible Age

18 Years

Maximum Eligible Age

42 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean Olivier Arnaud

Role: STUDY_DIRECTOR

Assistance Publique Hôpitaux de Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Biologie de la Reproduction

Marseille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Odile Lacroix-Paulmyer, PUPH

Role: CONTACT

Phone: +33 (0)4 91 38 13 78

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Odile Lacroix-Paulmyer, PUPH

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-20

Identifier Type: -

Identifier Source: org_study_id